In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

Baby Boomers looking to put new money to work may wish to check out the broader basket of dividend stocks while interest ...

Pfizer's drug combination improves survival in prostate cancer patients. Starboard Value pressures Pfizer over board conduct.

Pfizer's combination of Talzenna and Xtandi has shown a notable improvement in overall survival rates for patients with metastatic castration-resistant prostate cancer (mCRPC) in a late-stage study.

On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...

DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ...